APHA Stock Forecast: Aphria Inc plummets as cannabis sector gets hammered


  • NASDAQ:APHA drops by 6.70% as the broader markets experience a small correction on Thursday.
  • Aphria and Tilray both crash as the cannabis heavyweights prepare for their impending merger.
  • Analysts side with Aphria as Tillray continues to get downgrades from Wall Street.

NASDAQ:APHA has had a stellar 2021 so far like much of the cannabis industry has, but that came to a screeching halt on Thursday as the broader markets hit a minor speed bump. Aphria’s stock fell by 6.70% and closed the bumpy trading session at $19.23, which is still well above its 50-day and 200-day moving averages. The Ontario, Canada-based company has rewarded its investors so far this year returning over 160% even though the stock has fallen since peaking at a 52-week high of $32.29 earlier this month. 

Much of the talk around Aphria this year has revolved around its impending merger with Tilray (NASDAQ:TLRY), one of the leaders of the Canadian cannabis industry. Tilray surprised Wall Street and investors this past week with a better than expected earnings report which included strong fourth-quarter revenues and steadily growing margins. Despite this, several analysts still downgraded Tilray for the long-run, citing that the Nanaimo-based firm may not be strong enough to stand on its own for much longer. The merger with Aphria seems to be happening at just the right time for Tilray, which also saw its stock fall by 14% on Thursday. 

APHA stock price

APHA stock price chart

Aphria CEO Irwin Simon will be running the new merger which will still operate under the Aphria brand. Both companies will look to leverage each other as they plan to expand operations into Europe’s medicinal marijuana market once the deal is settled. At this point, with European countries already legalizing cannabis for medical use, the continent may be a more profitable point of entry as the United States still awaits federal legalization. Besides, there are already plenty of American cannabis companies in operation for when that legislation inevitably occurs. 

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD clings to daily gains above 1.0650

EUR/USD clings to daily gains above 1.0650

EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.

EUR/USD News

GBP/USD recovers toward 1.2450 after UK Retail Sales data

GBP/USD recovers toward 1.2450 after UK Retail Sales data

GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.

GBP/USD News

Gold holds steady at around $2,380 following earlier spike

Gold holds steady at around $2,380 following earlier spike

Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.

Gold News

Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium

Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in

Bitcoin price shows no signs of directional bias while it holds above  $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research. 

Read more

Week ahead – US GDP and BoJ decision on top of next week’s agenda

Week ahead – US GDP and BoJ decision on top of next week’s agenda

US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.

Read more

Forex MAJORS

Cryptocurrencies

Signatures